GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SMO Clinplus Co Ltd (SZSE:301257) » Definitions » EV-to-EBIT

SMO Clinplus Co (SZSE:301257) EV-to-EBIT : 9.87 (As of Jun. 06, 2024)


View and export this data going back to 2022. Start your Free Trial

What is SMO Clinplus Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SMO Clinplus Co's Enterprise Value is ¥1,553.5 Mil. SMO Clinplus Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥157.4 Mil. Therefore, SMO Clinplus Co's EV-to-EBIT for today is 9.87.

The historical rank and industry rank for SMO Clinplus Co's EV-to-EBIT or its related term are showing as below:

SZSE:301257' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.76   Med: 26.21   Max: 68.07
Current: 9.88

During the past 7 years, the highest EV-to-EBIT of SMO Clinplus Co was 68.07. The lowest was 5.76. And the median was 26.21.

SZSE:301257's EV-to-EBIT is ranked better than
72.73% of 99 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.82 vs SZSE:301257: 9.88

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SMO Clinplus Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥2,122.2 Mil. SMO Clinplus Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ¥157.4 Mil. SMO Clinplus Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.42%.


SMO Clinplus Co EV-to-EBIT Historical Data

The historical data trend for SMO Clinplus Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SMO Clinplus Co EV-to-EBIT Chart

SMO Clinplus Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - - 26.07 18.47

SMO Clinplus Co Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.78 19.09 20.44 18.47 13.48

Competitive Comparison of SMO Clinplus Co's EV-to-EBIT

For the Diagnostics & Research subindustry, SMO Clinplus Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SMO Clinplus Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SMO Clinplus Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SMO Clinplus Co's EV-to-EBIT falls into.



SMO Clinplus Co EV-to-EBIT Calculation

SMO Clinplus Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1553.451/157.416
=9.87

SMO Clinplus Co's current Enterprise Value is ¥1,553.5 Mil.
SMO Clinplus Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥157.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SMO Clinplus Co  (SZSE:301257) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SMO Clinplus Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=157.416/2122.239
=7.42 %

SMO Clinplus Co's Enterprise Value for the quarter that ended in Mar. 2024 was ¥2,122.2 Mil.
SMO Clinplus Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥157.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SMO Clinplus Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SMO Clinplus Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


SMO Clinplus Co (SZSE:301257) Business Description

Traded in Other Exchanges
N/A
Address
No. 105 Sinan Road, Room 108, Building 1, Huangpu District, Shanghai, CHN, 200001
SMO Clinplus Co Ltd is engaged in providing SMO services to domestic and foreign pharmaceutical companies, medical device companies and clinical research and development of some health-related products. The services provided include Preliminary model establishment, Preliminary plan preparation, Initiation of clinical trial sites, On-site implementation, and Comprehensive project management.
Executives
Lai Chun Bao Director
Ma Lin Director

SMO Clinplus Co (SZSE:301257) Headlines

No Headlines